Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

A Phase 1/2a, Open-Label Study to Evaluate the Safety and Efficacy of a Single Intravenous Infusion of BC-U001, a Human Umbilical Cord-Derived Mesenchymal Stem Cell Product, for Rheumatoid Arthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04971980
• Other study ID #: BC-U001-RA2019
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 12, 2021
• Est. completion date: January 2023

Study information

• Verified date: January 2022
• Source: Beijing Baylx Biotech Co., Ltd.
• Contact: Libo Zheng
• Phone: +86-010-56865685-2074
• Email: zhenglibo[@]blswinc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BC-U001 is an allogeneic fresh human umbilical cord-derived mesenchymal stem cell product, which showed therapeutic potential for rheumatoid arthritis(RA) based on its anti-inflammatory, immunomodulatory and tissue repair activities. The primary objective of this open-label, non-randomized, dose-escalation study is to evaluate the safety and tolerability of a single intravenous infusion of BC-U001 for RA patients using a 3+3 design.

Description:

This study will enroll RA patients who still remained moderate-to-high disease activity after conventional synthetic DMARDs (csDMARDs) therapy. All participants are informed about the study procedures and potential risks and are required to provide written informed consent prior to study begin. A 3+3 dose escalation design will be implemented. Three ascending dose cohorts (3 participants/cohort) will be treated successively to identify the maxium tolerated dose (MTD) and/or a recommended dose for phase II study. Dose escalation will be terminated if the dose-limiting toxicities (DLT) are observed in 2 participants during the 28-day follow-up within cohort. DLT was defined as any ≥grade 3 non-hematological toxicity or grade 4 hemtological toxicity according to CTCAE v5.0, which was related to the investigational product determined by investigator.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: January 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female patients aged 18 to 65 (inclusive)

2. Patients who are diagnosed with rheumatoid arthritis following the 2010 ACR/EULAR classification criteria

3. Patients who still remain moderate-to-high disease activity, i.e. DAS28>3.2 at screening and study baseline, after standard csDMARDs therapy

4. Patients who are positive for rheumatoid factors (RF) and/or anti-CCP antibody

5. Patients who are clinically stable with no significant changes in physical condition from screening to study baseline

6. Patients who are available and willing to comply with all study procedures

7. Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines

Exclusion Criteria:

1. Infections of hepatitis B, hepatitis C, active or latent tuberculosis, or positive for human immunodeficiency virus (HIV)1 or HIV2

2. Any history of ongoing, significant infections or recent serious infection, i.e., requiring hospitalization and or IV antimicrobial treatment in the 3 months prior to screening

3. Any active inflammatory diseases other than RA

4. Serum aminotransferase (ALT or AST) levels = 2x upper limits of normal

5. Creatinine clearance rate (Ccr) < 45 ml/min calculated by Cockcroft-Gault formula

6. Severe chronic obstructive pulmonary disease or known lung disease except for mild asthma treated with bronchodilators

7. Any coexistent active major medical diagnosis of clinically significant cardiovascular, neurological psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion

8. History of cerebrovascular accident (stroke) within 1 year before screening

9. Clinically significant heart disease (New York Heart Association, class III and class IV)

10. Surgery or trauma (e.g. contusions, abrasions, stab wounds, cutting wounds, crush injuries, impact injuries, and firearm injuries etc.) within 14 days before enrollment that are not approporiate to participate in study in investigators' opinion

11. Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study and for twelve months after completing the study infusion, unless surgically sterilized or postmenopausal during the study

12. Corticosteroid usage at a high dose (i.e., IV or IM corticosteroids or use of oral prednisone equivalent >10 mg/day) or not at a stable dose for the treatment of RA or other diseases within 28 days prior to randomization.

13. Known allergies or had a history of allergy to minor molecular heparinum and human serum albumin that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion

14. Already participating in another interventional clinical trial or participated in another interventional clinical trial within 3 months before screening

15. Clinical history of malignancy with the exception of adequately treated cervical carcinoma in situ or basal cell carcinomas

16. Other situations that are not approporiate to participate in study in investigators' opinion

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• hUC-MSC infusion (BC-U001)
The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10^6 cells/kg body weight, 1.0x10^6 cells/kg body weight, 1.5x10^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital (Dongdan campus)	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Baylx Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and frequency of adverse events (AEs)	Adverse events are assessed by CTCAE 5.0 up to 28±3 days. The flexible change of ±3 days is set for the convenience of patients. Day 1 refers to the day the participant accept BC-U001 infusion.	Up to day 28±3
Primary	Changes of vital signs from 1 hour after infusion to day 28±3		Up to day 28±3
Primary	Changes of complete blood count (CBC) from day 1 to day 28±3		Up to day 28±3
Primary	Changes of blood biochemical from day 1 to day 28±3		Up to day 28±3
Primary	Changes of coagulation function from day 1 to day 28±3		Up to day 28±3
Primary	Routine urine analysis		Up to day 28±3
Primary	Urine pregnancy test (female only)		28±3 days
Primary	Cardiac rate measured by twelve-lead electrocardiogram		Up to day 28±3
Secondary	Percentage of participants achieving ACR20		Up to day 28±3
Secondary	Percentage of participants achieving ACR50		Up to day 28±3
Secondary	Percentage of participants achieving ACR70		Up to day 28±3
Secondary	Change from baseline of the disease activity score based on DAS28-CRP		Up to day 28±3
Secondary	Change from baseline of the disease activity score based on DAS28-ESR		Up to day 28±3
Secondary	EULAR response		Up to day 28±3
Secondary	Change from baseline of the health assessment questionnaire(HAQ) score		Up to day 28±3
Secondary	Change from baseline of the simplified disease activity index (SDAI) score		Up to day 28±3
Secondary	Change from baseline of the clinical disease activity index (CDAI) score		Up to day 28±3
Secondary	Change from baseline of TNF-a level		Up to day 28±3
Secondary	Change from baseline of IL-6 level		Up to day 28±3